Evidence map›Paper›PMID 38438738›Full record

ArticleArchives of toxicology2024

Genetic variants in m5C modification genes are associated with survival of patients with HBV-related hepatocellular carcinoma.

Bowen Chen, Moqin Qiu, Rongbin Gong, Yingchun Liu, Zihan Zhou, Qiuping Wen, Xiaoxia Wei, Xiumei Liang, Yanji Jiang, Peiqin Chen and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. The m5C orchestrator NSUN7 drives SPARC/HMGB1 axis-mediated inflammation to exacerbate kidney injury.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. mFrontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Bowen Chen *Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Moqin Qiu *Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Rongbin Gong *Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Yingchun LiuDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Zihan ZhouDepartment of Cancer Prevention and Control, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Qiuping WenDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Xiaoxia WeiDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Xiumei LiangDepartment of Disease Process Management, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Yanji JiangDepartment of Scientific Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
Peiqin ChenDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Yuying WeiDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Qiongguang HuangDepartment of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, 530021, China.
Qiuyan MoDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.
Qiuling LinDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, China. linqiuling@stu.gxmu.edu.cn.ORCID 0000-0002-3239-4345
Hongping YuDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China. yuhongping@stu.gxmu.edu.cn.
Guangxi Medical University · CN

Funding

Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education GKE-ZZ202316The 111 Projects D17011Youth Science Foundation of Guangxi Medical University GXMUYSF202304Youth Science Foundation of Guangxi Medical University GXMUYSF202312
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high mortality rate. The 5-methylcytosine (m5C), a type of RNA modification, plays crucial regulatory roles in HCC carcinogenesis, metastasis, and prognosis. However, a few studies have investigated the effect of genetic variants in m5C modification genes on survival of patients with hepatitis B virus (HBV)-related HCC. In the present study, we evaluated associations between 144 SNPs in 15 m5C modification genes and overall survival (OS) in 866 patients with the HBV-related HCC. Expression quantitative trait loci (eQTL) analysis and differential expression analysis were conducted to investigate biological mechanisms. As a result, we identified that two SNPs (NSUN7 rs2437325 A > G and TRDMT1 rs34434809 G > C) were significantly associated with HBV-related HCC OS with adjusted allelic hazards ratios of 1.25 (95% confidence interval = 1.05-1.48 and P = 0.011) and 1.19 (1.02-1.38 and P = 0.027), respectively, with a trend of combined risk genotypes (P

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsGenotypeHepatitis B virusHumansPrognosisRNA, MessengerRNA, MessengerGenetic variantsHepatitis B virusHepatocellular carcinomam5C modificationSurvival

Identifiers

PMID38438738
OpenAlexW4392367061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.